Search Results - michael+jung

15 Results

Sort By:

Inhibitors of the N-terminal Domain of the Androgen Receptor (UCLA Case No. 2023-075)

Researchers at UCLA under the guidance of Drs. Matthew Rettig and Michael Jung have developed novel molecular compounds that reduce growth of prostate cancer cells. Dr. Jung in collaboration with Dr. Rettig have furthered the development of these compounds by synthesizing a new series of analogues that have similar inhibitory effects. BACKGROUND: Prostate...

Published: 9/23/2024 | Inventor(s): Matthew Rettig, Michael Jung

Keywords(s): androgen receptor therapy, castration resistant prostate cancer, Oncology, Oncology (Small Molecules, Peptides and Antibodies), prostate cancer, small molecules

Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

Compounds and Methods for Treating Cancer by Destroying Cancer Stem Cells (UCLA Case No. 2021-286)

Researchers from UCLA’s Department of Chemistry and Biochemistry and the Department of Radiation Oncology have synthesized a set of compounds for the eradication of cancer stem cells. These compounds are predicted to cross the blood brain barrier and show promise as effective interventions for glioblastoma in both in vitro and in vivo assays. BACKGROUND:...

Published: 7/11/2024 | Inventor(s): Michael Jung, Frank Pajonk

Keywords(s): blood-brain barrier, Brain, Cancer, Cancer stem cells, drug screening, GBM, Glioblastoma, Glioma, new chemical entity

Category(s): Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Stem Cells And Regenerative Medicine

Development of Novel Compounds to Suppress Neuronal Stress and Cross the Blood Brain Barrier (UCLA Case No. 2021-165)

SUMMARY: An interdisciplinary group of UCLA researchers have developed and validated a library of compounds that alleviate symptoms of Rett Syndrome and hold enormous therapeutic potential for the long-term treatment of other intellectual disability syndromes. BACKGROUND: Intellectual disability (ID) affects more than 100 million people globally and...

Published: 5/8/2024 | Inventor(s): William Lowry, Michael Jung, Xiaoguang Liu, Elena Korsakova

Keywords(s): blood-brain barrier, Drug, intellectual disability, Organoids, senescence

Category(s): Therapeutics > CNS and Neurology, Life Science Research Tools, Diagnostic Markers > Targets And Assays

A novel ER beta ligand prodrug to treat neurodegenerative conditions (UCLA Case No. 2017-168)

Researchers from the Department of Neurology and the Department of Chemistry and Biochemistry at UCLA have developed a novel ERβ ligand prodrug that is structurally designed to confer neuroprotection in neurodegenerative conditions (multiple sclerosis, Alzheimer’s disease, and cognitive deficits of menopause in otherwise healthy women). BACKGROUND: Multiple...

Published: 1/24/2024 | Inventor(s): Rhonda Voskuhl, Michael Jung

Keywords(s): Autoimmune, Cns, Therapeutics & Vaccines

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Autoimmune, Therapeutics

2017-094: Inhibitors of the N-Terminal Domain of the Androgen Receptor

SUMMARYUCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.BACKGROUNDProstate...

Published: 7/19/2023 | Inventor(s): Matthew Rettig, Michael Jung

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

2020-832: Novel Compounds Targeting APOE4 That Enhance Brain SIRT1 Levels and Target Novel Mechanism of Action

Researchers at UCLA's Drug Discovery Lab and Department of Chemistry have developed new chemical entity (NCE) analogs of A03, which together form a new class of compounds that target apolipoprotein E4 (ApoE4)-mediated deficits in the tau deacetylase enzyme, sirtuin 1 (SirT1). These NCEs provide an opportunity for novel therapeutic development in Alzheimer's...

Published: 9/5/2023 | Inventor(s): Varghese John, Jesus Campagna, Michael Jung

Keywords(s): Brain

Category(s): Therapeutics

2012-601 Development of a New Approach to Kill Human Non-Small Cell Lung Cancer Stem Cells

Novel Small Molecules that Target Cancer Stem Cells for the Treatment of CancerBACKGROUNDLung cancer is the leading cause of cancer related death in the United States. In 2012, it is estimated that approximately 230,000 patients will be newly diagnosed, and since more than 160,000 individuals will succumb to this disease, there exists an urgent need...

Published: 7/19/2023 | Inventor(s): Michael Jung, Richard Pietras, Diana Marquez Garban, Gang Deng

Keywords(s): Oncology (Small Molecules, Peptides and Antibodies), Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > Oncology > Oncology (Small Molecules)

2019-958 SELECTIVE HDAC INHIBITORS

UCLA researchers in the Department of Chemistry and Biochemistry have synthesized a series of novel hydroxamic acids and derivatives as selective histone deacetylase (HDAC) inhibitors from simple starting materials.BACKGROUND:Histone deacetylase (HDAC) inhibitors are chemical compounds that regulates gene expression by inhibiting histone deacetylases....

Published: 7/19/2023 | Inventor(s): Michael Jung, Jonghoon Kim

Keywords(s): Chemical Manufacturing & Industrial/Bulk Chemicals, Cns, Gene Editing Systems, Gene Therapy, Infectious Diseases, Inflammatory Diseases, Therapeutics & Vaccines

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Infectious Diseases, Therapeutics > Gene Therapy And Editing, Therapeutics > Inflammation And Inflammatory Diseases, Chemical > Industrial & Bulk Chemicals

2015-829 Novel Antiviral Compounds

Novel Antiviral Compounds to Treat Enterovirus InfectionsSUMMARYResearchers in UCLA Department of Molecular & Medical Pharmacology have used a rapid, live virus assay to develop potent enterovirus inhibitors.BACKGROUNDHuman enteroviruses (EVs) are a genus of more than 110 serologically distinct, small, non-enveloped RNA viruses responsible for poliomyelitis...

Published: 9/14/2023 | Inventor(s): Paul Krogstad, Michael Jung, Jun Zuo, Yanpeng Xing

Keywords(s): Infectious Diseases, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > Infectious Diseases

2016-518: Inhibition of Protein Tyrosine Phosphatase-Sigma for Hematopoietic Regeneration

Inhibition Of Protein Tyrosine Phosphatase - Sigma For Hematopoietic RegenerationSUMMARYUCLA Researchers have identified a novel pharmacological target for hematopoietic stem cell regeneration. They have developed small molecule inhibitors against the target and shown that the inhibitors cause rapid stem cell regeneration.BACKGROUNDDepletion of white...

Published: 7/19/2023 | Inventor(s): John Chute, Michael Jung, Emelyne Diers

Keywords(s): Autoimmune, Hematology, Inflammatory Diseases, iPS/stem cells, Oncology

Category(s): Therapeutics > Autoimmune, Therapeutics > Oncology, Therapeutics > Hematology, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Stem Cells And Regenerative Medicine > Ips Stem Cells

1 2